Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

AMIVANTAMAB-VMJW: 2,005 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
2,005
Total FAERS Reports
159 (7.9%)
Deaths Reported
362
Hospitalizations
2,005
As Primary/Secondary Suspect
41
Life-Threatening
7
Disabilities
Prescription
Status

FDA Application: 761210 ·

First Report: 202106 · Latest Report: 20250923

What Are the Most Common AMIVANTAMAB-VMJW Side Effects?

#1 Most Reported
Infusion related reaction
509 reports (25.4%)
#2 Most Reported
Rash
315 reports (15.7%)
#3 Most Reported
Off label use
130 reports (6.5%)

All AMIVANTAMAB-VMJW Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Infusion related reaction 509 25.4% 17 88
Rash 315 15.7% 9 29
Off label use 130 6.5% 17 20
Dyspnoea 81 4.0% 6 14
Paronychia 78 3.9% 0 5
Nausea 65 3.2% 6 9
Oxygen saturation decreased 55 2.7% 2 15
Flushing 54 2.7% 4 4
Death 53 2.6% 53 12
Non-small cell lung cancer 51 2.5% 21 7
Fatigue 46 2.3% 2 8
Product dose omission issue 45 2.2% 1 4
Hypotension 44 2.2% 4 4
Stomatitis 44 2.2% 0 18
Skin toxicity 42 2.1% 3 4
Pyrexia 41 2.0% 5 19
Dermatitis acneiform 40 2.0% 1 12
Diarrhoea 40 2.0% 5 17
Oedema peripheral 38 1.9% 2 7
Chest discomfort 37 1.9% 0 3

Who Reports AMIVANTAMAB-VMJW Side Effects? Age & Gender Data

Gender: 64.4% female, 35.6% male. Average age: 66.0 years. Most reports from: US. View detailed demographics →

Is AMIVANTAMAB-VMJW Getting Safer? Reports by Year

YearReportsDeathsHosp.
2021 34 0 3
2022 63 8 10
2023 87 10 22
2024 292 24 96
2025 325 22 100

View full timeline →

What Is AMIVANTAMAB-VMJW Used For?

IndicationReports
Product used for unknown indication 1,064
Non-small cell lung cancer 366
Non-small cell lung cancer metastatic 187
Lung neoplasm malignant 128
Egfr gene mutation 89
Lung adenocarcinoma 67
Bronchial carcinoma 15
Non-small cell lung cancer recurrent 12
Lung cancer metastatic 11
Metastatic bronchial carcinoma 11

AMIVANTAMAB-VMJW vs Alternatives: Which Is Safer?

AMIVANTAMAB-VMJW vs AMLODIPINE AMIVANTAMAB-VMJW vs AMLODIPINE BESILATE AMIVANTAMAB-VMJW vs AMLODIPINE\ATORVASTATIN AMIVANTAMAB-VMJW vs AMLODIPINE\BENAZEPRIL AMIVANTAMAB-VMJW vs AMLODIPINE\HYDROCHLOROTHIAZIDE\OLMESARTAN AMIVANTAMAB-VMJW vs AMLODIPINE\HYDROCHLOROTHIAZIDE\OLMESARTAN MEDOXOMIL AMIVANTAMAB-VMJW vs AMLODIPINE\HYDROCHLOROTHIAZIDE\VALSARTAN AMIVANTAMAB-VMJW vs AMLODIPINE\INDAPAMIDE\PERINDOPRIL AMIVANTAMAB-VMJW vs AMLODIPINE\INDAPAMIDE\PERINDOPRIL ARGININE AMIVANTAMAB-VMJW vs AMLODIPINE\OLMESARTAN MEDOXOMIL

Official FDA Label for AMIVANTAMAB-VMJW

Official prescribing information from the FDA-approved drug label.